Curanex Pharmaceuticals (CURX)


Market Price (11/21/2026): $4.44 | Market Cap: $7.0 MilSector: Health Care | Industry: Biotechnology

Curanex Pharmaceuticals (CURX)


Market Price (11/21/2026): $4.44
Market Cap: $7.0 Mil
Sector: Health Care
Industry: Biotechnology

Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.

0

Cash is significant % of market cap
Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -16%

Weak multi-year price returns
2Y Excs Rtn is -121%, 3Y Excs Rtn is -159%

Very low revenue
Rev LTMTotal Revenue or Sales, Last Twelve Months is 0

Not profitable at operating income level
Op Inc LTMOperating Income, Last Twelve Months is -12 Mil

Yield minus risk free rate is negative
ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -190%

Key risks
CURX key risks include [1] uncertain clinical trial outcomes for its lead candidate, Show more.

0 Cash is significant % of market cap
Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -16%
1 Weak multi-year price returns
2Y Excs Rtn is -121%, 3Y Excs Rtn is -159%
2 Very low revenue
Rev LTMTotal Revenue or Sales, Last Twelve Months is 0
3 Not profitable at operating income level
Op Inc LTMOperating Income, Last Twelve Months is -12 Mil
4 Yield minus risk free rate is negative
ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -190%
5 Key risks
CURX key risks include [1] uncertain clinical trial outcomes for its lead candidate, Show more.

Valuation & Metrics

Price Chart

Why The Stock Moved

Qualitative Assessment

AI Analysis | Feedback

Prices as of 11/20/2026

Nov 19: down 5.5% in one day (S&P 500 down 2.0%)
The stock fell without company news. The broader market also fell, with headlines reporting a market wipeout and troubling economic signals that day.

Down 29.0% since its Nov 6 high (S&P 500 down 6.2%)
The stock declined throughout this period without company-specific news, and the broader market also moved down. Its largest drops were on November 13 and November 11, also including November 19.

Show more
Prices as of 11/20/2026

Nov 19: down 5.5% in one day (S&P 500 down 2.0%)
The stock fell without company news. The broader market also fell, with headlines reporting a market wipeout and troubling economic signals that day.

Down 29.0% since its Nov 6 high (S&P 500 down 6.2%)
The stock declined throughout this period without company-specific news, and the broader market also moved down. Its largest drops were on November 13 and November 11, also including November 19.

Show less
Holding a concentrated position? Know your true downside before the momentum shifts.
Protect Your Wealth →

Stock Movement Drivers

Fundamental Drivers

The 7.5% change in CURX stock from 7/31/2026 to 11/20/2026 was primarily driven by a 0.0% change in the company's Total Revenues ($ Mil).
(LTM values as of)731202611202026Change
Stock Price ($)4.104.417.5%
Change Contribution By: 
Total Revenues ($ Mil)000.0%
P/S Multiple∞∞0.0%
Shares Outstanding (Mil)12-6.5%
Cumulative Contribution0.0%

LTM = Last Twelve Months as of date shown

Market Drivers

7/31/2026 to 11/20/2026
ReturnCorrelation
CURX7.5% 
Market (SPY)-7.4%10.7%
Sector (XLV)9.5%15.1%

Fundamental Drivers

The -47.1% change in CURX stock from 4/30/2026 to 11/20/2026 was primarily driven by a -6.4% change in the company's Shares Outstanding (Mil).
(LTM values as of)430202611202026Change
Stock Price ($)8.344.41-47.1%
Change Contribution By: 
Total Revenues ($ Mil)000.0%
P/S Multiple∞∞0.0%
Shares Outstanding (Mil)12-6.4%
Cumulative Contribution0.0%

LTM = Last Twelve Months as of date shown

Market Drivers

4/30/2026 to 11/20/2026
ReturnCorrelation
CURX-47.1% 
Market (SPY)-3.5%11.2%
Sector (XLV)22.4%12.3%

Fundamental Drivers

The -67.5% change in CURX stock from 10/31/2025 to 11/20/2026 was primarily driven by a -8.5% change in the company's Shares Outstanding (Mil).
(LTM values as of)1031202511202026Change
Stock Price ($)13.554.41-67.5%
Change Contribution By: 
Total Revenues ($ Mil)000.0%
P/S Multiple∞∞0.0%
Shares Outstanding (Mil)12-8.5%
Cumulative Contribution0.0%

LTM = Last Twelve Months as of date shown

Market Drivers

10/31/2025 to 11/20/2026
ReturnCorrelation
CURX-67.5% 
Market (SPY)2.2%11.3%
Sector (XLV)24.9%6.8%

Fundamental Drivers

null
null

Market Drivers

10/31/2023 to 11/20/2026
ReturnCorrelation
CURX  
Market (SPY)71.0%10.2%
Sector (XLV)49.6%7.4%

Return vs. Risk

Price Returns Compared

 202120222023202420252026Total [1]
Returns
CURX Return-----92%-33%-95%
Peers Return5%-40%-24%47%110%16%71%
S&P 500 Return27%-19%24%23%16%8%97%

Monthly Win Rates [3]
CURX Win Rate----20%45% 
Peers Win Rate56%44%44%50%61%55% 
S&P 500 Win Rate75%42%67%75%67%36% 

Max Drawdowns [4]
CURX Max Drawdown------65% 
Peers Max Drawdown-44%-62%-59%-34%-44%-37% 
S&P 500 Max Drawdown-5%-25%-10%-8%-19%-9% 


[1] Cumulative total returns since the beginning of 2021
[2] Peers: KYMR, NKTR, ABBV.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 11/20/2026 (YTD)

How Low Can It Go

CURX has limited trading history. Below is the Health Care sector ETF (XLV) in its place.

EventXLVS&P 500
2025 US Tariff Shock
  % Loss-11.7%-18.8%
  % Gain to Breakeven13.3%23.1%
  Time to Breakeven142 days79 days
2022 Inflation Shock & Fed Tightening
  % Loss-13.8%-24.5%
  % Gain to Breakeven15.9%32.4%
  Time to Breakeven166 days427 days
2020 COVID-19 Crash
  % Loss-27.9%-33.7%
  % Gain to Breakeven38.8%50.9%
  Time to Breakeven77 days140 days
Q4 2018 Fed Policy Error / Growth Scare
  % Loss-15.0%-19.2%
  % Gain to Breakeven17.6%23.8%
  Time to Breakeven191 days105 days
2015-2016 China Devaluation / Global Growth Scare
  % Loss-15.9%-12.2%
  % Gain to Breakeven18.9%13.9%
  Time to Breakeven165 days62 days
2011 US Debt Ceiling Crisis & European Contagion
  % Loss-15.8%-17.9%
  % Gain to Breakeven18.8%21.8%
  Time to Breakeven153 days123 days

Compare to KYMR, NKTR, ABBV

In The Past

State Street Health Care Select Sector SPDR ETF's stock fell -11.7% during the 2025 US Tariff Shock. Such a loss loss requires a 13.3% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

CURX has limited trading history. Below is the Health Care sector ETF (XLV) in its place.

EventXLVS&P 500
2020 COVID-19 Crash
  % Loss-27.9%-33.7%
  % Gain to Breakeven38.8%50.9%
  Time to Breakeven77 days140 days
2008-2009 Global Financial Crisis
  % Loss-37.9%-53.4%
  % Gain to Breakeven61.1%114.4%
  Time to Breakeven767 days1085 days

Compare to KYMR, NKTR, ABBV

In The Past

State Street Health Care Select Sector SPDR ETF's stock fell -11.7% during the 2025 US Tariff Shock. Such a loss loss requires a 13.3% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

About Curanex Pharmaceuticals (CURX)

N/A

AI Analysis | Feedback

null

AI Analysis | Feedback

null

AI Analysis | Feedback

null

AI Analysis | Feedback

null

AI Analysis | Feedback

Jun Liu Chief Executive Officer, Chairman of the Board and President

Jun Liu was appointed as President and Chairman of the Board of Curanex Pharmaceuticals Inc. in February 2024. In March 2026, a four-year executive employment agreement formalized his ongoing leadership, entrusting him with overall responsibility for the company's management, corporate strategy, research and development oversight, clinical and regulatory coordination, capital markets activities, and business execution. He directly owns 24.97% of the company's shares.

Wanjun Zhang Chief Financial Officer and Treasurer

Wanjun Zhang was appointed Chief Financial Officer and Treasurer of Curanex Pharmaceuticals Inc. effective January 1, 2026. He is 52 years old and brings over 20 years of experience in financial and accounting roles, with expertise in financial reporting, compliance, and business strategy. Prior to joining Curanex, Mr. Zhang provided financial consulting and accounting services to small and medium-sized companies since July 2020. He previously served as finance director at Beijing Huaxiahuitong Petty Loan Co. Ltd. from July 2017 to July 2020 and as finance director at Perfect World (Beijing) Software Co., Ltd., a former NASDAQ-listed company, from August 2010 to February 2016. Mr. Zhang holds a Bachelor's degree in Accounting from the Central University of Finance and Economics in Beijing, China.

Dr. Ning Zhang, PhD Chief Technology Officer

Dr. Ning Zhang holds the position of Chief Technology Officer at Curanex Pharmaceuticals.

Dr. Liqin Xie, PhD Chief Operating Officer

Dr. Liqin Xie serves as the Chief Operating Officer of Curanex Pharmaceuticals Inc. An at-will executive employment agreement for Dr. Xie became effective on March 1, 2026. She is involved in the operational aspects of the company's drug development, including milestones such as the completion of GMP-compliant pilot-scale batches for drug candidates.

Dr. Huijuan Zhong Chief Science Officer and Director

Dr. Huijuan Zhong is the Chief Science Officer and a Director at Curanex Pharmaceuticals.

AI Analysis | Feedback

The key risks for Curanex Pharmaceuticals (CURX) primarily stem from its status as a developmental-stage pharmaceutical company with no current revenue-generating products.

  1. Clinical Development and Regulatory Approval Risk: As a preclinical-stage pharmaceutical company, Curanex Pharmaceuticals' success is heavily reliant on the successful progression of its lead botanical drug candidate, Phyto-N, through rigorous preclinical studies, Investigational New Drug (IND) submission, and subsequent clinical trials. The company is currently targeting an IND submission for ulcerative colitis in the fourth quarter of 2026, with Phase I clinical trials expected to follow. Failures at any stage of development, delays in regulatory approvals, or unexpected adverse effects could significantly impede its ability to bring products to market, which is a common and critical risk for companies in this industry.
  2. Financial Sustainability and Cash Runway: Curanex Pharmaceuticals reported negative net income and no revenue in the past year, indicating a reliance on external funding for its operations. The company has a limited cash runway, less than one year, suggesting that it will need to secure additional financing in the near future to continue its drug development programs. While its current liquidity and solvency are excellent with no outstanding debt, this financial health is based on its recent initial public offering in August 2025, which raised $15 million. Sustaining operations and advancing drug candidates without a commercialized product poses a significant financial risk.
  3. High Stock Volatility and Low Liquidity: The company's stock is characterized by high volatility and is considered "very high risk" due to periodic low trading volume. Such volatility can lead to significant fluctuations in share price, making it a speculative investment. Low liquidity can also make it challenging for investors to buy or sell shares without significantly impacting the stock price.

AI Analysis | Feedback

null

AI Analysis | Feedback

Curanex Pharmaceuticals (CURX) Addressable Markets for Main Products and Services

Curanex Pharmaceuticals (CURX) is a developmental-stage pharmaceutical company focused on discovering and developing botanical drugs for inflammatory diseases. Its lead candidate, Phyto-N, is being developed for several indications, with ulcerative colitis being the primary focus.

The addressable markets for Curanex Pharmaceuticals' main product indications are as follows, with market sizes provided globally:

  • Ulcerative Colitis: The global ulcerative colitis market size was valued at approximately USD 6.59 billion in 2024 and is projected to reach USD 9.72 billion by 2033. Other estimates place the global market at USD 8.3 billion in 2025, growing to USD 14.9 billion by 2035.
  • Atopic Dermatitis: The global atopic dermatitis drugs market size was valued at approximately USD 12.1 billion in 2024 and is estimated to grow to USD 31 billion by 2034.
  • Type 2 Diabetes: The global Type 2 Diabetes market size was valued at approximately USD 36.7 billion in 2024 and is projected to reach USD 71.55 billion by 2033.
  • Nonalcoholic Fatty Liver Disease (NAFLD): The global NAFLD drug market size is estimated to be around USD 21.98 billion in 2025 and is predicted to increase to approximately USD 33.6 billion by 2034.
  • Gout: The global gout treatment market size was valued at approximately USD 2.40 billion in 2024 and is expected to reach USD 4.75 billion by 2032. Another report estimates the global gout therapeutics market at USD 3.0 billion in 2025, growing to USD 5.7 billion by 2035.

AI Analysis | Feedback

Curanex Pharmaceuticals (CURX) is a developmental-stage biotechnology company focused on discovering, developing, and commercializing botanical drugs for inflammatory diseases. The company's future revenue growth over the next 2-3 years is primarily anticipated to be driven by progress in its lead drug candidate and strategic advancements in its pipeline.

Here are 3-5 expected drivers of future revenue growth for Curanex Pharmaceuticals:

  1. Advancement of Phyto-N for Ulcerative Colitis: Curanex's lead botanical drug candidate, Phyto-N, is primarily focused on treating moderate to severe ulcerative colitis. The company has recently completed a Good Manufacturing Practice (GMP)-compliant pilot-scale batch of Phyto-N. Curanex plans to submit an Investigational New Drug (IND) application for ulcerative colitis and initiate Phase I clinical trials in the fourth quarter of 2026. Successful progression through these regulatory and clinical milestones will be a critical driver for future revenue potential.
  2. Expansion into Multiple Therapeutic Indications for Phyto-N: Beyond ulcerative colitis, Phyto-N is in preclinical research for several other inflammatory conditions, including atopic dermatitis, COVID-19, type 2 diabetes, nonalcoholic fatty liver disease (NAFLD), and gout. Advancing Phyto-N through development for these additional indications would significantly broaden the drug's market potential and open new avenues for revenue generation.
  3. Strategic Licensing Agreements and Commercialization: As a developmental-stage company, Curanex Pharmaceuticals anticipates revenue generation only upon successful commercialization of its products or through strategic licensing agreements. Future partnerships or licensing deals with larger pharmaceutical entities for Phyto-N or other pipeline candidates could provide crucial funding, milestone payments, and eventual royalties, thereby driving revenue growth.
  4. Leveraging Botanical Drug Development Approach: Curanex emphasizes its unique botanical drug development approach, which aims for high-efficacy botanical drugs with de-risked clinical pathways. The company highlights that Phyto-N has a history of human use over 30 years in China, demonstrating favorable tolerability and providing extensive preclinical data across multiple indications. This established safety profile and scientific backing for its botanical programs could expedite regulatory approvals and market acceptance, serving as a competitive advantage and a driver for accelerated commercialization.

AI Analysis | Feedback

Share Issuance

  • Curanex Pharmaceuticals completed its Initial Public Offering (IPO) in August 2025, issuing 3.75 million shares of common stock at $4.00 per share, generating gross proceeds of $15 million.
  • The underwriters fully exercised their over-allotment option in September 2025, purchasing an additional 562,500 shares at $4.00 each, resulting in an additional $2.25 million in gross proceeds and bringing the total gross proceeds from the IPO to $17.25 million.
  • The company issued 28,312 shares of its common stock to an investor for $200,000 in a private placement in September 2025.

Inbound Investments

  • The company received $200,000 from investor Xiaohong Song through a private placement of common stock in September 2025.
  • Curanex Pharmaceuticals received loans totaling $400,000 from Dian Ying Jing, the company's secretary and spouse of the chief executive officer, in February and May 2025, which were subsequently repaid in September 2025.

Capital Expenditures

  • Net proceeds from the August 2025 IPO, approximately $12.87 million, are intended to fund the development of its lead product candidate, Phyto-N, for ulcerative colitis, including FDA-required toxicology and pharmacokinetic studies, and preparation of an Investigational New Drug (IND) application.
  • As of September 30, 2025, Curanex reported $8.47 million in prepaid research and development with Contract Research Organizations (CROs) and Contract Development and Manufacturing Organizations (CDMOs).
  • In February 2026, Curanex completed a Good Manufacturing Practice (GMP)-compliant pilot-scale batch of its lead botanical drug candidate, Phyto-N, a key manufacturing milestone supporting upcoming toxicology and pharmacokinetic studies for a planned IND submission in Q4 2026.

Peer Outperformance in Biotechnology

CURX has trailed 59% of its 452 Biotechnology peers over 1Y. Biotechnology ranks 9th of 10 industries in Health Care by median 5Y return. The sector’s gains have largely come from elsewhere.
Share of Biotechnology constituents that CURX has outperformed, by holding period. Peers without a full price history over a given window are excluded from that window.
1Y
41%
of 452 industry peers · -47.6% return
3Y
—
insufficient price history
5Y
—
insufficient price history
No Biotechnology peer with a comparable growth profile has beaten CURX by more than 20pp over 1Y.
Median price return by industry across the Health Care sector, ranked by 5Y. Biotechnology is CURX's own industry. Use this to see which corners of the sector have carried the returns.
Industry Names 1Y med3Y med5Y med Top 3 by 5Y
Health Care Distributors 5 17.3%74.7%198.5% CAH 523% · MCK 396% · COR 198%
Health Care Services 20 30.7%20.5%14.0% RDNT 146% · HIMS 100% · DGX 92%
Managed Health Care 8 60.1%-12.7%-9.2% OSCR 140% · HQY 54% · ELV 2%
Health Care Facilities 26 13.2%13.0%-10.4% THC 240% · NHC 211% · EHC 187%
Health Care Equipment 50 -2.1%6.7%-19.0% GKOS 393% · UFPT 319% · TMDX 274%
Health Care Supplies 11 19.9%-4.3%-41.8% LNTH 256% · HAE 114% · MMSI 22%
Pharmaceuticals 61 -16.1%-0.2%-42.0% LQDA 1178% · KNSA 670% · XERS 648%
Life Sciences Tools & Services 110 -25.7%-28.8%-76.5% AXGN 471% · MEDP 169% · NTRA 165%
Biotechnology ← 370 -35.9%-45.4%-85.2% ELVN 1310% · DNTH 1164% · TRVI 1159%
Health Care Technology 23 -26.4%-56.9%-86.5% VEEV -13% · DOCS -53%
Median of constituents with a full price history over each window. Top names are limited to companies above $2B market cap.

Recent Active Movers

Peer Comparisons

Peers to compare with:

Financials

CURXKYMRNKTRABBVMedian
NameCuranex .Kymera T.Nektar T.AbbVie  
Mkt Price4.44124.1030.27286.2677.19
Mkt Cap0.012.41.0506.46.7
Rev LTM01025266,01477
Op Inc LTM-12-405-15823,749-85
FCF LTM-4-289-25718,872-131
FCF 3Y Avg-5-222-20918,060-107
CFO LTM-4-288-25720,089-131
CFO 3Y Avg-5-213-20819,153-106

Growth & Margins

CURXKYMRNKTRABBVMedian
NameCuranex .Kymera T.Nektar T.AbbVie  
Rev Chg LTM-133.8%-16.6%10.7%10.7%
Rev Chg 3Y Avg-56.9%-14.6%6.3%6.3%
Rev Chg Q--100.0%-20.4%10.3%-20.4%
QoQ Delta Rev Chg LTM--2.6%-4.4%2.5%-2.6%
Op Inc Chg LTM-919.7%-23.3%-16.2%65.3%-19.7%
Op Inc Chg 3Y Avg--32.4%-3.3%17.8%-3.3%
Op Mgn LTM--396.0%-303.6%36.0%-303.6%
Op Mgn 3Y Avg--456.7%-222.4%29.2%-222.4%
QoQ Delta Op Mgn LTM--66.2%-64.2%2.0%-64.2%
CFO/Rev LTM--281.3%-492.4%30.4%-281.3%
CFO/Rev 3Y Avg--314.9%-328.4%31.7%-314.9%
FCF/Rev LTM--282.6%-493.4%28.6%-282.6%
FCF/Rev 3Y Avg--326.1%-329.5%29.9%-326.1%

Valuation

CURXKYMRNKTRABBVMedian
NameCuranex .Kymera T.Nektar T.AbbVie  
Mkt Cap0.012.41.0506.46.7
P/S-121.519.87.719.8
P/Op Inc-0.5-30.7-6.521.3-3.5
P/EBIT-0.5-35.6-7.332.1-3.9
P/E-0.5-35.6-5.849.0-3.2
P/CFO-1.6-43.2-4.025.2-2.8
Total Yield-184.4%-3.0%-17.2%4.4%-10.1%
Dividend Yield0.0%0.0%0.0%2.4%0.0%
FCF Yield 3Y Avg--3.8%-31.8%4.5%-3.8%
D/E0.10.00.10.20.1
Net D/E-0.2-0.1-0.50.1-0.1

Returns

CURXKYMRNKTRABBVMedian
NameCuranex .Kymera T.Nektar T.AbbVie  
1M Rtn-11.4%10.2%-20.9%0.5%-5.4%
3M Rtn-5.7%3.6%-59.1%8.7%-1.1%
6M Rtn-33.0%57.3%-54.6%34.5%0.7%
12M Rtn-47.2%92.0%-45.1%28.5%-8.3%
3Y Rtn-94.5%554.5%329.4%128.0%228.7%
1M Excs Rtn-11.4%15.4%-18.5%3.6%-3.9%
3M Excs Rtn-1.0%5.8%-55.8%12.0%2.4%
6M Excs Rtn-32.3%58.1%-53.8%35.2%1.5%
12M Excs Rtn-61.4%78.9%-61.5%14.9%-23.3%
3Y Excs Rtn-159.6%516.4%219.5%65.1%142.3%

Comparison Analyses

null

Financials

Segment Financials

Revenue by Segment
$ Mil202420232022
Single Segment000
Total000


Assets by Segment
$ Mil2025202420232022
Single Segment12100
Total12100


Price Behavior

Price Behavior
Market Price$4.41 
Market Cap ($ Bil)0.0 
First Trading Date03/11/2010 
Distance from 52W High-58.3% 
   50 Days200 Days
DMA Price$4.97$6.07
DMA Trendupdown
Distance from DMA-11.2%-27.3%
 3M1YR
Volatility88.1%97.3%
Downside Capture218.51185.14
Upside Capture252.5886.76
Correlation (S&P 500)10.1%11.6%
CURX Betas & Captures as of 10/31/2026

 1M2M3M6M1Y3Y
Beta1.051.8417.9311.385.57-36.91
Up Beta4.332.30-225.09-142.78-53.87-12.26
Down Beta-4.78-3.18-2.56-0.400.090.58
Up Capture405%504%19115%6491%2474%264%
Bmk +ve Days12182862130427
Stock +ve Days10212448102123
Down Capture269%211%225%195%149%110%
Bmk -ve Days10253664121325
Stock -ve Days11212755126150

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
Annualized
Return
Annualized
Volatility
Sharpe
Ratio
Correlation
with CURX
CURX-51.0%97.7%-0.31-
Sector ETF (XLV)18.4%17.1%0.806.9%
Equity (SPY)5.2%14.4%0.1111.7%
Gold (GLD)-13.9%29.3%-0.527.0%
Commodities (DBC)28.2%21.5%1.05-5.1%
Real Estate (VNQ)8.6%14.3%0.336.4%
Bitcoin (BTCUSD)-32.4%43.7%-0.7814.3%

Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
Annualized
Return
Annualized
Volatility
Sharpe
Ratio
Correlation
with CURX
CURX-44.3%128.8%-0.86-
Sector ETF (XLV)7.5%15.4%0.297.2%
Equity (SPY)9.6%17.4%0.3910.4%
Gold (GLD)13.1%19.3%0.534.7%
Commodities (DBC)6.6%19.6%0.220.2%
Real Estate (VNQ)0.5%19.0%-0.088.4%
Bitcoin (BTCUSD)-0.7%51.4%0.1714.2%

Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
Annualized
Return
Annualized
Volatility
Sharpe
Ratio
Correlation
with CURX
CURX-25.3%128.8%-0.86-
Sector ETF (XLV)11.4%16.8%0.557.2%
Equity (SPY)14.1%18.1%0.6610.4%
Gold (GLD)10.4%16.6%0.504.7%
Commodities (DBC)7.2%18.2%0.310.2%
Real Estate (VNQ)5.9%20.7%0.248.4%
Bitcoin (BTCUSD)56.2%66.3%0.9614.2%

Smart multi-asset allocation framework can stack odds in your favor. Learn How

Short Interest

Short Interest: As Of Date10302026
Short Interest: Shares Quantity0.0 Mil
Short Interest: % Change Since 1015202614.4%
Average Daily Volume0.0 Mil
Days-to-Cover Short Interest1
Basic Shares Quantity1.5 Mil
Short % of Basic Shares0.4%

Earnings Returns History

Updated 6/3/2026
Expand for More
 Forward Returns
Earnings Date1D Returns5D Returns21D Returns
SUMMARY STATS   
# Positive000
# Negative000
Median Positive   
Median Negative   
Max Positive   
Max Negative   
Collapse to Preview
 Forward Returns
Earnings Date1D Returns5D Returns21D Returns
SUMMARY STATS   
# Positive000
# Negative000
Median Positive   
Median Negative   
Max Positive   
Max Negative   

SEC Filings

Expand for More
Report DateFiling DateFiling
09/30/202611/13/202610-Q
06/30/202608/14/202610-Q
03/31/202605/14/202610-Q
12/31/202503/30/202610-K
09/30/202511/17/202510-Q
06/30/202509/09/202510-Q
03/31/202508/26/2025424B4
09/30/202411/01/2024S-1/A
06/30/202410/16/2024S-1
Collapse to Preview
Report DateFiling DateFiling
09/30/202611/13/202610-Q
06/30/202608/14/202610-Q
03/31/202605/14/202610-Q
12/31/202503/30/202610-K
09/30/202511/17/202510-Q
06/30/202509/09/202510-Q
03/31/202508/26/2025424B4
09/30/202411/01/2024S-1/A
06/30/202410/16/2024S-1
Core Cache Last Updated: 11/20/2026